1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,610 | 6,850 | 06.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Insilico Medicine appoints new VP of clinical development for oncology | 1 | Investing.com | ||
| Fr | Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology | 104 | PR Newswire | CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico") (3696.HK), a clinical-stage biotechnology company powered by generative artificial... ► Artikel lesen | |
| Do | Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications | 44 | PR Newswire | NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1ß and IL-18, and ISM5059 targets systemic inflammatory... ► Artikel lesen | |
| Di | Listed IPO INSILICO Spikes 13% to Log New Listing High on $39M Milestone Payment Received Following First-in-patient Dosing for MEN2501 | 2 | AASTOCKS | ||
| Di | INSILICO (03696): VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE RECEIVES HKD39 MILLION MILESTONE PAYMENT FROM MENARINI GROUP FOLLOWING FIRST-IN-HUMAN ACHIEVEMENT ... | 1 | HKEx | ||
| 28.01. | Insilico and Qilu Pharmaceutical sign deal for cardiometabolic therapies | 1 | Pharmaceutical Technology | ||
| 27.01. | Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies | 414 | PR Newswire | CAMBRIDGE, Mass., Jan. 27, 2026 /PRNewswire/ -- Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group... ► Artikel lesen | |
| 27.01. | Qilu programs path into cardiometabolic disease with $120M, AI-enabled Insilico alliance | 2 | FierceBiotech | ||
| INSILICO MEDICINE Aktie jetzt für 0€ handeln | |||||
| 27.01. | INSILICO Reaches $900M+ Drug Development Collaboration with Qilu Pharmaceutical | 1 | AASTOCKS | ||
| 27.01. | INSILICO (03696): VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE AND QILU PHARMACEUTICAL ENTER INTO DRUG DEVELOPMENT COLLABORATION VALUED AT OVER HKD931 MILLION ... | 2 | HKEx | ||
| 23.01. | Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor | 182 | PR Newswire | Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) paves the way for ISM8969 clinical study in the United States. The Phase... ► Artikel lesen | |
| 23.01. | INSILICO (03696): VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE RECEIVES IND APPROVAL FROM FDA FOR ISM8969, AN AI-EMPOWERED POTENTIAL BEST-IN-CLASS NLRP3 INHIBITOR | 2 | HKEx | ||
| 22.01. | INSILICO (03696): STABILIZING ACTIONS AND END OF STABILIZATION PERIOD | 1 | HKEx | ||
| 21.01. | INSILICO (03696): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 21.01. | Insilico agrees on $66M deal to split rights for preclinical NLRP3 inhibitor with new Chinese biotech | 7 | FierceBiotech | ||
| 21.01. | Insilico, Hygtia Therapeutics Partner To Advance ISM8969 NLRP3 Inhibitor For CNS Disorders | 1 | RTTNews | ||
| 21.01. | Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment | 352 | PR Newswire | Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have entered into an exclusive license... ► Artikel lesen | |
| 20.01. | INSILICO (03696): VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE AND HYGTIA THERAPEUTICS ENTER INTO GLOBAL STRATEGIC COLLABORATION VALUED AT OVER HKD500 MILLION ... | 1 | HKEx | ||
| 16.01. | INSILICO (03696): FULL EXERCISE OF THE OVER-ALLOTMENT OPTION | 2 | HKEx | ||
| 15.01. | InSilico lands drug discovery deal after Hong Kong IPO | 5 | Bamboo Works |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 41,400 | -2,82 % | HV-Termine: Hauptversammlungen bei Adv. Blockchain, Aurubis, Fortec, Schott, Siemens, Healthineers, Stabilus, TUI | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,640 | +0,40 % | Fresenius Medical Care: Ein Neuanfang nach turbulenten Zeiten? | ||
| FRESENIUS | 49,760 | +1,06 % | JEFFERIES stuft Fresenius SE auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Fresenius mit einem Kursziel von 55 Euro auf "Buy" belassen. Die Bad Homburger seien in Verjüngungskur, und der Markt preise... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 28,740 | +4,89 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 39,680 | +3,44 % | BrightSpring Health Services, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 | ||
| CARL ZEISS MEDITEC | 27,520 | +0,66 % | BARCLAYS stuft CARL ZEISS MEDITEC AG auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Carl Zeiss Meditec von 49 auf 32 Euro gesenkt und die Aktien von "Overweight" auf "Equal Weight" abgestuft. Nur... ► Artikel lesen | |
| HEARTFLOW | 27,690 | +6,54 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| GENEDX | 84,35 | +0,32 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 21,990 | +2,23 % | Privia Health Group, Inc.: Privia Health Reports Third Quarter 2025 Financial Results | Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1%... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 21,750 | +2,84 % | 6 Analysts Have This To Say About Alignment Healthcare | ||
| GERRESHEIMER | 25,660 | +1,99 % | JEFFERIES stuft GERRESHEIMER AG auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Gerresheimer mit einem Kursziel von 34,10 Euro auf "Buy" belassen. Analyst James Vane-Tempest zählt den Spezialverpackungshersteller... ► Artikel lesen | |
| PROGYNY | 21,960 | +0,18 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| HIMS & HERS HEALTH | 19,500 | +0,15 % | BREAKING: Hims & Hers verschärft Preisdruck bei Novo Nordisk - Aktie beschleunigt Talfahrt | Der dänische Biopharma-Riese ist erst seit wenigen Wochen mit seinem Appetitzügler Wegovy als Tablette auf dem US-Markt und sieht sich einem massiven Preisdruck ausgesetzt. Das Telehealth-Unternehmen... ► Artikel lesen | |
| UNITEDHEALTH | 232,15 | -0,77 % | UnitedHealth: Das sieht gar nicht gut aus | Der enttäuschende Ausblick, den UnitedHealth dem Kapitalmarkt vor Kurzem an die Hand gegeben hat, und maue Aussichten für 2027 hinterlassen weitere Spuren im Aktienkurs des größten US-Krankenversicherers.... ► Artikel lesen | |
| RXSIGHT | 8,390 | +7,29 % | RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer | ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following... ► Artikel lesen |
INSILICO MEDICINE CAYMAN TOPCO gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 6,850 Euro und damit +1,78 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INSILICO MEDICINE CAYMAN TOPCO finden Sie auf Wallstreet Online.